ENSC
Ensysce Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.46
+1.24%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$0.45
From 52W high−82.18%
Volume493570.00
Market cap$8.91M
P/E (TTM)—
P/S (TTM)7.7x
Div yield—
Key dataSep 18, 2026
Open
$0.45
From 52W high
−82.18%
Volume
493570.00
Market cap
$8.91M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
P/E (TTM)
—
RSI (14)
56.6
MomentumView details →
1D Return
+1.24%
YTD Return
−50.49%
SummaryUpdated Jun 1, 2026
Ensysce Biosciences, Inc. (NASDAQ:ENSC) is a clinical-stage pharmaceutical company founded in 2018 and based in La Jolla, California. The company specializes in developing abuse-resistant and overdose-protection opioid medications to address the ongoing opioid crisis in the United States. Since going public in March 2018, Ensysce has focused on advancing its proprietary drug delivery platforms through clinical trials while generating revenue from licensing agreements and research collaborations.
Similar companies
Latest newsMore news →
Ensysce Biosciences hosted a symposium on its CRPS program at PainWeek 2026, attended by more than 320 pain management professionals.5d agoRichard Langford, Chief Medical Officer of Cy Biopharma, was selected to present at the U.S. Food and Drug Administration's public hearing on the potential future therapeutic use of psychedelic drugs, held on September 14, 2026 at the FDA's White Oak Campus in Silver Spring, Maryland.6d agoEnsysce Biosciences, Inc. announced a private placement financing.33d ago